Latest KaloBios Pharmaceuticals Inc. Stories
SOUTH SAN FRANCISCO, Calif., May 14, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer, announced today its financial results for the first quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) "KaloBios marked the first quarter of 2013...
SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics. (Logo:...
SOUTH SAN FRANCISCO, Calif., April 24, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has been selected to present at the 12(th) Annual Needham Healthcare Conference, to be held in New York City on April 30-May 1, 2013. KaloBios Chief Financial Officer, Jeffrey H. Cooper, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics....
CHICAGO, April 23, 2013 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), and KaloBios Pharmaceuticals (Nasdaq: KBIO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an antibody fragment, intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients. The...
SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection." (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) Mr. Pritchard will be discussing the...
SOUTH SAN FRANCISCO, Calif., April 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company has been selected to present at the 2013 BioCentury-Thomson Reuters Future Leaders in the Biotech Industry Conference, to be held in New York City on April 5, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted...
SOUTH SAN FRANCISCO, Calif., March 27, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced financial results for fiscal year 2012. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) Financial Highlights ($ in millions, except per share data, unaudited) FY 2012 FY 2011 Percent Change -------...
TEL AVIV, Israel, February 27, 2013 /PRNewswire/ -- Bioassociate has initiated coverage on KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO). The Initiation Report contains a detailed discussion of KaloBios' business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks. The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications. Dr. Ofir Levi, Bioassociate's CEO:...
Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas. The findings demonstrated preliminary...
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share. Gross proceeds from the offering were $70 million, and net proceeds were approximately $62 million, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by the company. Leerink Swann LLC acted as sole book-running...
